TFCT-NIB 5MG TAB

About

TFCT-NIB 5MG TAB contains tofacitinib, an oral Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes that transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane, influencing various cellular processes including immune function and inflammation. Tofacitinib selectively inhibits JAK1 and JAK3, and to a lesser extent JAK2, thereby interfering with the signaling pathways of several cytokines involved in the pathogenesis of autoimmune and inflammatory diseases.

By modulating these signaling pathways, tofacitinib reduces the production of inflammatory mediators and the activity of immune cells, leading to a decrease in inflammation and disease progression. It is a targeted synthetic disease-modifying antirheumatic drug (tsDMARD) used in the treatment of chronic inflammatory conditions. Its mechanism offers a distinct approach compared to traditional immunosuppressants or biologics, providing an effective option for patients who have not responded adequately to other therapies.

Uses

• Treatment of moderate to severe rheumatoid arthritis.
• Management of psoriatic arthritis.
• Treatment of moderate to severe ulcerative colitis.
• Management of ankylosing spondylitis.

Directions For Use

Take one tablet orally with or without food, twice daily or as directed by your healthcare professional.

Benefits

• Reduces joint pain and swelling.
• Slows progression of joint damage.
• Improves physical function.
• Effective for inflammatory bowel disease.
• Oral administration, not injectable.
• Targets specific inflammatory pathways.

Side Effects

• Upper respiratory tract infections
• Headache
• Diarrhea
• Nausea
• Nasopharyngitis
• Urinary tract infections
• Herpes zoster (shingles)
• Anemia
• Increased cholesterol levels
• Increased liver enzymes
• Serious infections (e.g., tuberculosis, fungal)
• Lymphoma and other malignancies (rare)

Safety Measures

• Alcohol - Alcohol does not directly interact with tofacitinib, but excessive intake can exacerbate underlying inflammatory conditions or liver issues.
• Pregnancy - Not recommended during pregnancy. Consult a doctor; use only if potential benefits justify the potential risk to the fetus.
• Breastfeeding - Tofacitinib is excreted in breast milk. Avoid breastfeeding during treatment and for at least 18 hours after the last dose.
• Liver - Use with caution in patients with liver impairment. Dose adjustment may be necessary, and liver function should be monitored regularly.
• Kidney - Dose adjustment is required in patients with moderate to severe kidney impairment due to reduced clearance of the drug.
• Lung - Use with caution in patients with pre-existing lung conditions, especially those with a history of chronic lung disease or interstitial lung disease, due to infection risk.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.